254 related articles for article (PubMed ID: 23527295)
21. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Margot NA; Isaacson E; McGowan I; Cheng A; Miller MD
J Acquir Immune Defic Syndr; 2003 May; 33(1):15-21. PubMed ID: 12792350
[TBL] [Abstract][Full Text] [Related]
22. Diverse approaches useful for microbicide trials.
Abdool Karim SS; Abdool Karim Q
Nature; 2007 Sep; 449(7158):24. PubMed ID: 17805274
[No Abstract] [Full Text] [Related]
23. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Betancor G; Garriga C; Puertas MC; Nevot M; Anta L; Blanco JL; Pérez-Elías MJ; de Mendoza C; Martínez MA; Martinez-Picado J; Menéndez-Arias L; ; Iribarren JA; Caballero E; Ribera E; Llibre JM; Clotet B; Jaén A; Dalmau D; Gatel JM; Peraire J; Vidal F; Vidal C; Riera M; Córdoba J; López Aldeguer J; Galindo MJ; Gutiérrez F; Álvarez M; García F; Pérez-Romero P; Viciana P; Leal M; Palomares JC; Pineda JA; Viciana I; Santos J; Rodríguez P; Gómez Sirvent JL; Gutiérrez C; Moreno S; Pérez-Olmeda M; Alcamí J; Rodríguez C; del Romero J; Cañizares A; Pedreira J; Miralles C; Ocampo A; Morano L; Aguilera A; Garrido C; Manuzza G; Poveda E; Soriano V
Retrovirology; 2012 Aug; 9():68. PubMed ID: 22889300
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Keller MJ; Madan RP; Torres NM; Fazzari MJ; Cho S; Kalyoussef S; Shust G; Mesquita PM; Louissaint N; Chen J; Cohen HW; Diament EC; Lee AC; Soto-Torres L; Hendrix CW; Herold BC
PLoS One; 2011 Jan; 6(1):e16475. PubMed ID: 21283552
[TBL] [Abstract][Full Text] [Related]
25. Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
Dezzutti CS; Russo J; Wang L; Abebe KZ; Li J; Friend DR; McGowan IM; Rohan LC
PLoS One; 2014; 9(7):e102585. PubMed ID: 25025306
[TBL] [Abstract][Full Text] [Related]
26. HIV transmission may be prevented by intravaginal tenofovir ring.
Parks L
Future Med Chem; 2012 Dec; 4(18):2239. PubMed ID: 23359902
[No Abstract] [Full Text] [Related]
27. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.
Chan PA; Huang A; Kantor R
J Int AIDS Soc; 2012 Oct; 15(2):17701. PubMed ID: 23305651
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Clark MR; Friend DR
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
[TBL] [Abstract][Full Text] [Related]
29. AIDS: Drugs that prevent HIV infection.
Wainberg MA
Nature; 2011 Jan; 469(7330):306-7. PubMed ID: 21248832
[No Abstract] [Full Text] [Related]
30. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
Adams JL; Kashuba AD
Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):451-62. PubMed ID: 22306523
[TBL] [Abstract][Full Text] [Related]
31. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ;
HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684
[TBL] [Abstract][Full Text] [Related]
33. Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
Karim QA; Baxter C; Karim SA
BJOG; 2014 Oct; 121 Suppl 5(0 5):53-61. PubMed ID: 25335841
[TBL] [Abstract][Full Text] [Related]
34. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Chi BH; Ellis GM; Chintu N; Cantrell RA; Sinkala M; Aldrovandi GM; Warrier R; Mbewe F; Nakamura K; Stringer EM; Frenkel LM; Stringer JS
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
[TBL] [Abstract][Full Text] [Related]
35. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
[TBL] [Abstract][Full Text] [Related]
37. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
38. Topical microbicides for preventing sexually transmitted infections.
Obiero J; Ogongo P; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007961. PubMed ID: 33719075
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
Grohskopf LA; Chillag KL; Gvetadze R; Liu AY; Thompson M; Mayer KH; Collins BM; Pathak SR; Oʼhara B; Ackers ML; Rose CE; Grant RM; Paxton LA; Buchbinder SP
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):79-86. PubMed ID: 23466649
[TBL] [Abstract][Full Text] [Related]
40. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
